Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Abbott Receives FDA Authorization for Blood Test to Detect Zika Virus



According to the company, this is the first commercial molecular test to be authorized by the US Food and Drug Administration (FDA) to detect Zika in whole blood samples.

Share this!

February 6, 2017 | by Sarah Hand, M.Sc.

Diagnostics maker Abbott, has announced that their RealTime Zika test has been approved to detect the virus in whole blood samples, for emergency use. According to the company, this is the first commercial molecular test to be authorized by the US Food and Drug Administration (FDA) to detect Zika in whole blood samples.

Compared to serum and urine samples, the Zika virus can be detected in whole blood samples for a longer time period as the pathogen remains in the blood at higher levels. One of the conditions of the authorization of Abbott’s Zika test is that the whole blood sample be collected from a patient alongside a serum or plasma sample.

“Diagnosing a Zika infection can be challenging, especially since people might not have any symptoms or only have mild symptoms that last a few days,” said Dr. John Hackett, divisional vice president, applied research and technology, Diagnostics Products, Abbott. “Abbott's molecular test may provide the ability to identify the active virus over a longer time period with whole blood and could provide a more accurate diagnosis. Our test can also distinguish Zika from other viruses such as dengue or chikungunya, which helps doctors make informed diagnoses to help people get back to better health.”

The RealTime Zika test is compatible with Abbott’s m2000 RealTime System, which is used as a molecular diagnostics instrument in hospitals and reference laboratories in the US and other countries. The test is highly sensitive and produces results in five to seven hours.

The diagnostic is also automated, making it less labor-intensive for laboratory staff. This automation also helps mitigate the risk of human error, and reduces the wait time for results.

While media coverage of the Zika virus outbreak has diminished, the World Health Organization (WHO) still believes that Zika is a major public health challenge. While the infection is often asymptomatic, it has been linked to serious birth defects, making it important that possible cases are diagnosed early.

Keywords: FDA, Zika Virus, Diagnostic


Share this with your colleagues!

Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News

Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News

Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


One Patient’s Perspective on Clinical Trials


Planning and Conducting Trials of the Latest Immunotherapies

ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation

Medical Devices: Reviewing Regulatory Changes in the US and EU

Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.